Katherine Pearce, MD
Internal Medicine · Baton Rouge, LANPI 1871593368
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,526 of the $11,322 with a category attached, or 84.1%. It is spread thinly across 51 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 541 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Modernatx, Inc.$1K
- Novartis$954
- Novo Nordisk$785
- Astellas Pharma US Inc$727
- Boehringer Ingelheim$652
- plus $5K from 45 others
Across 3,666 payments — averaging $3257.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$8.1M
- Seqirus USA Inc$1.3M
- Amgen$1.3M
- Vertex$798K
- Novavax Inc$168K
- GSK$123K
- plus $202K from 4 others
What the payments were for
- Travel & lodging$1,67115%
- Food & beverage$9,52684%
- Education$1251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$160
How this compares
$11,322 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 134 | $162,053 |
| OzempicSemaglutide | 124 | $153,181 |
| JardianceEmpagliflozin | 129 | $116,026 |
| TrulicityDulaglutide | 38 | $43,957 |
| MyrbetriqMirabegron | 31 | $35,529 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $20,921 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $16,383 |
| EliquisApixaban | 18 | $16,170 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $11,810 |
| JanuviaSitagliptin Phosphate | 14 | $11,305 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,677 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,448 |
| Atorvastatin Calcium | 675 | $6,790 |
| Risedronate Sodium | 55 | $4,865 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 113 | $4,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $649 | $206,010172 claims |
| Novo NordiskOzempic | $785 | $153,181124 claims |
| Boehringer IngelheimJardiance | $652 | $116,026129 claims |
| Astellas Pharma US IncMyrbetriq | $727 | $35,52931 claims |
| GSKTrelegy Ellipta | $408 | $16,38323 claims |
| PfizerEliquis | $319 | $16,17018 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $336 | $11,81012 claims |
| MerckJanuvia | $226 | $11,30514 claims |
| AbbVieSynthroid | $1,970 | $4,43560 claims |
| AstraZenecaSymbicort | $72 | $4,07818 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $39 | $2,450295 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Baton Rouge
- Donna RyanBaton Rouge$991K
- John SchwabBaton Rouge$122K
- Barret MurphyBaton Rouge$43K
- Brian GremillionBaton Rouge$27K
- Bradley MeekBaton Rouge$20K
- Leo BlaizeBaton Rouge$17K
- Michael HymbaughBaton Rouge$16K
- Kyle ChampagneBaton Rouge$16K
- Charles HalliburtonBaton Rouge$16K
- Hartman BruntBaton Rouge$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.